Results 61 to 70 of about 495 (142)

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment. [PDF]

Eur J Health Econ, 2023
Gandjour A.
europepmc   +1 more source

Teme, motivi i simboli u pjesmama divanskih pjesnika iz Bosne i Hercegovine

Anali Gazi Husrev-Begove Biblioteke, 1990
The poetic creations of 16th and 17th century divan poets from Bosnia and Herzegovina is analysed with regard to the themes and motives found in this poetry.
Fehim Nametak
doaj  

Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion. [PDF]

J Cancer Res Clin Oncol, 2023
Bartol A, Dressler K, Kaskel P, Landsberg C, Lechner C, Petschulies M.   +5 more
europepmc   +1 more source

In Reply. [PDF]

Dtsch Arztebl Int, 2023
Lordick F, Merz M, Aigner A.
europepmc   +1 more source

Access in all areas? A round up of developments in market access and health technology assessment: part 2. [PDF]

J Comp Eff Res, 2023
Beattie A, Treharne C, Mardiguian S, Ramagopalan SV.   +3 more
europepmc   +1 more source

Priming Perception and it's Influence on Brand Personality in Perspective of Consumer Behaviour [PDF]

, 2007
This Ph.D. thesis focuses on how priming perception influence the development of brand personality in perspecitve of Consumer Behaviour. Three main deep empirical studies has been made in order to show the relationship and common interaction amnog the ...
Víteček, David
core  

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG? [PDF]

Appl Health Econ Health Policy, 2022
Dintsios CM, Chernyak N.
europepmc   +1 more source

Sonderstatus von Orphan Drugs im AMNOG : Zwischenbilanz des Verfahrens zur Nutzenbewertung und ökonomische Untersuchung der kritischen Umsatzgrenze [PDF]

Hintergrund: Die Umsatzschwelle für die Nutzenbewertung von Arzneimitteln zur Behandlung eines seltenen Leidens wurde durch das GKV-Finanzstabilisierungsgesetz von 50 Mio. auf 30 Mio. Euro gesenkt.
Kapprell, Luca
core  

Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? [PDF]

J Mark Access Health Policy
Kloc K, Toumi M, Łukomska E, Kowalska M, Tyrała-Chowaniec I, Simoens S, Wasem J, Boyer L, Dussart C, Auquier P.   +9 more
europepmc   +1 more source

Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany. [PDF]

J Pharm Policy Pract
Ardito V, Falk L, Gasol Boncompte M, Pontes C, Robinson J, Schreyögg J, Ciani O.   +6 more
europepmc   +1 more source